Cancers, Vol. 12, Pages 1400: Urinary Biomarkers in Bladder Cancer: Where Do We Stand and Potential Role of Extracellular Vesicles
Cancers, Vol. 12, Pages 1400: Urinary Biomarkers in Bladder Cancer: Where Do We Stand and Potential Role of Extracellular Vesicles Cancers doi: 10.3390/cancers12061400 Authors: Manuel Castanheira de Oliveira Hugo R. Caires Maria J. Oliveira Avelino Fraga M. Helena Vasconcelos Ricardo Ribeiro Extracellular vesicles (EVs) are small membrane vesicles released by all cells and involved in intercellular communication. Importantly, EVs cargo includes nucleic acids, lipids, and proteins constantly transferred between different cell types, contributing to autocrine and paracrine signaling. In recent years, they have been shown to play vital roles, not only in normal biological functions, but also in pathological conditions, such as cancer. In the multistep process of cancer progression, EVs act at different levels, from stimulation of neoplastic transformation, proliferation, promotion of angiogenesis, migration, invasion, and formation of metastatic niches in distant organs, to immune escape and therapy resistance. Moreover, as products of their parental cells, reflecting their genetic signatures and phenotypes, EVs hold great promise as diagnostic and prognostic biomarkers. Importantly, their potential to overcome the current limitations or the present diagnostic procedures has created interest in bladder cancer (BCa). Indeed, cystoscopy is an invasive and costly technique, whereas cytology has poor sensitivity for early staged and low-grade disease. Several urine...
Authors: Jensen JB PMID: 32643516 [PubMed - as supplied by publisher]
Authors: Malmström PU PMID: 32633178 [PubMed - as supplied by publisher]
CONCLUSIONS: We have identified Let-7f-5p as a miRNA biomarker of recurrence in NMIBC tumors. We further demonstrate that targeting Lin28, a negative regulator of Let-7f-5p, represents a novel potential therapeutic opportunity in NMIBC. PMID: 32623385 [PubMed - as supplied by publisher]
ConclusionsSCC in SB can appear at a young age and is usually diagnosed in an advanced tumor stage with poor prognosis despite radical surgical resection. Patients with SB without BA with clinical symptoms, new onset of hematuria, and/or upper tract dilatation should receive a cystoscopy ± further imaging.
Conclusions: NBI appears to outperform 5-ALA and HAL in terms of diagnostic accuracy. All three modalities present high FPR, hence indicating the ability to detect additional cases and lesions beyond WLC.
ConclusionApproximately 18% of biopsies detected malignancy. While only small volumes of tissue are collected at flexible cystoscopy, these can help to distinguish malignancy from benign pathology. Our institution reports a non-diagnostic rate of approximately 11%, and in these cases, when there is still a suspicion of malignancy, a rigid cystoscopy and biopsy should be performed.
Matullo Barbara Pardini Bladder cancer (BC) is the tenth most frequent cancer worldwide. Due to the need for recurrent cystoscopies and the lack of non-invasive biomarkers, BC is associated with a high management burden. In this respect, small non-coding RNAs (sncRNAs) have been investigated in urine as possible biomarkers for BC, but in plasma their potential has not yet been defined. The expression levels of sncRNAs contained in plasma extracellular vesicles (EVs) from 47 men with BC and 46 healthy controls were assessed by next-generation sequencing. The sncRNA profiles were compared with urinary profiles from the...
AbstractPurpose of ReviewBladder augmentation and associated reconstructive procedures are a surgical option for patients with urologic congenital anomalies and neuropathic bladder with the goal of improving continence and reducing the risk of upper tract deterioration. Despite these benefits, augmentation also portends several short- and long-term potential complications. The goal of this chapter is to discuss these complications and review the current literature on this topic.Recent FindingsMetabolic abnormalities, including acid-base disorders and their sequelae, occur in 5 –15% of patients with bladder augmentati...
Conclusions: Our work demonstrates the current developments of a novel endoimaging system equipped with the potential to generate 3D bladder reconstructions from cystoscopy videos and AI-assisted automated detection of bladder tumors. PMID: 32491933 [PubMed - as supplied by publisher]
CONCLUSION: The success rate of this novel fiducial marker was 79% which is above the prospectively defined threshold rate. A distinct learning curve of the injection of the liquid marker was seen over the study period. The marker showed sustained visibility and positional stability during treatment phases and also appears to be safe and easy to inject. ADVANCES IN KNOWLEDGE: This novel liquid BioXmark® marker seem to be a very promising tool in daily-adaptive IGRT for bladder preserving chemo-radiotherapy in muscle invasive bladder cancer. PMID: 32463291 [PubMed - as supplied by publisher]